To identify drug-like RyR inhibitors that may be compatible with development as leads for either cardiac or neurodegenerative diseases, we used our established RyR-CaM FRET assays (32, 34) to screen the 50K-compound ChemBridge CNS library. The gene discussed is RYR2; the disease is neurodegenerative disease.